BCM
CDTX

BlueCrest Capital Management’s Cidara Therapeutics CDTX Stock Holding History

BlueCrest Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-722
Closed -$98K – 1494
2017
Q4 		$98K Buy
+722
New +$110K ﹤0.01% 765

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlueCrest Capital Management's CDTX Position: Q1 2018 in Review

BlueCrest Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2018, closing a stake of 722 shares — an estimated $98K sold.

BlueCrest Capital Management first reported a position in CDTX in Q4 2017 and held it in 1 quarter. The position peaked at $98K in Q4 2017. 60 funds tracked by Wall St. Rank hold CDTX as of Q1 2018.

  • BlueCrest Capital Management reported no remaining Cidara Therapeutics position as of Q1 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 722 Cidara Therapeutics shares in Q1 2018, an estimated $98K.
  • BlueCrest Capital Management first reported a position in Cidara Therapeutics in Q4 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Cidara Therapeutics position peaked at $98K in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2018.

Based on BlueCrest Capital Management's 13F filing for Q1 2018, filed 15 May 2018.